Homepage Top Section1

The IND includes results from completed toxicology, pharmacology, and manufacturing studies necessary for regulatory assessment. Pending IND clearance, Telomir Pharmaceuticals aims to start a Phase I/II clinical trial

Supported by Enterprise Singapore, the initiative aims to enhance Biophytis’ computational longevity platform and develop therapies for age-related diseases such as sarcopenia. The collaboration builds on Biophytis’ ongoing

The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low-

This marks the first domestic anti-PD-1 monoclonal antibody in a subcutaneous formulation to reach the marketing application stage. JS001sc is independently developed by Junshi Biosciences as a subcutaneous

CordenPharma Colorado will occupy the entire premises under a 15-year lease. The new LEED Gold-certified facility has flexible laboratory configurations, advanced mechanical and utility systems, and waste management

Following completion, the combined entity will operate as Candid Therapeutics and list on Nasdaq under the “CDRX” ticker symbol. As part of the merger, Candid has secured more

The recommendation applies to children aged two to 11 years experiencing moderate-to-severe CSU who do not respond adequately to histamine-1 antihistamines and are naïve to anti-immunoglobulin E (IgE) therapy.

The approval was granted by the US Food and Drug Administration (FDA) and follows positive AMPLIFY Phase III trial results. This trial enrolled patients from 2019 to 2021.

The partnership will combine Evogene’s computational chemistry capabilities with the expertise of Dr Mark Adams’ team at QUT, focusing on therapy-resistant non-small cell lung cancer (NSCLC) and other